Charles Bennett to Doxorubicin
This is a "connection" page, showing publications Charles Bennett has written about Doxorubicin.
Connection Strength
0.381
-
Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma. Acta Oncol. 1999; 38(8):1063-7.
Score: 0.141
-
Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Aug 15; 18(5):460-5.
Score: 0.137
-
Pharmacoeconomics of liposomal anthracycline therapy. Semin Oncol. 2004 Dec; 31(6 Suppl 13):191-5.
Score: 0.053
-
Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clin Cancer Res. 2011 Feb 01; 17(3):560-8.
Score: 0.020
-
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol. 2007 Jun; 137(6):545-52.
Score: 0.016
-
Staging and therapy of orbital lymphomas. Cancer. 1986 Mar 15; 57(6):1204-8.
Score: 0.014